Richard Pazdur, the former head of the FDA's Center for Drug Evaluation, who worked there for 26 years, abruptly left the agency last month. He warned of chaos at the FDA, where the line between political appointees and drug reviewers has been blurred. He criticized the lack of transparency in the new voucher program, which allows for expedited review of select drugs by the Trump administration. These meetings are held in a small conference room off Commissioner Marty Makary's office that cannot accommodate the entire review team. Pazdur stated that most of the participants in the meetings report directly to the commissioner, which he considers problematic. His departure raised concerns about FDA stability, including high staff turnover and drug approval delays. The Biotechnology Innovation Organization expressed concern over repeated turnover in key positions.[1][2][3][5]